Halogenated compounds, especially fluorine and chlorine, play a key role in drug development. They account for a large proportion of all approved drug molecules. The importance of these two halogens stems from their remarkable effects on biological activity and pharmacokinetic properties. The study presented here aims to give the results obtained by the DFT methods and in silico medicinal evaluations of a newly synthesized small molecule. The small molecule belongs to the Schiff base class of organic compounds and is substituted with halogen atoms. The tetrahalogenated compound (THSB) Schiff base, 2-(((2,4-dichlorophenyl)imino)methyl)-3,4-difluorophenol, was first synthesized via the classical condensation method and then characterized by spectroscopic techniques. The THSB optimized by the B3LYP method was evaluated in terms of geometrical parameters, surface area (MEP and Hirshfeld analysis) and secondary interaction analysis, NLO properties, and electronic properties (HOMO-LUMO and UV-Vis). Second, THSB was evaluated regarding medicinal chemistry, physicochemical and pharmacokinetic properties, and toxicity (ADMET). Then, we comprehensively investigated the potential biological targets of THSB. Using the results of the SwissSimilarity analysis, we investigated the antagonistic effects of THSB against serotonin 5-HT2A and dopamine D2 receptors. Docking results were compared with the known antipsychotics, clozapine and risperidone. THSB showed a higher antagonistic effect than clozapine for the D2 receptor. However, risperidone proved to be the most effective antagonist for both targets. The binding energies of THSB, risperidone, and clozapine were -8.30, -11.84, and -8.07 kcal/mol, respectively, for D2; those of THSB, risperidone, and clozapine were -6.94, -11.47, and -10.10 kcal/mol, respectively, for 5-HT2A.
None
None
I wish to thank Turan GÜÇLÜ for his technical help and valuable support.
None
Primary Language | English |
---|---|
Subjects | Engineering |
Journal Section | Chemistry |
Authors | |
Project Number | None |
Early Pub Date | August 1, 2023 |
Publication Date | March 1, 2024 |
Published in Issue | Year 2024 Volume: 37 Issue: 1 |